aref al-kali, md, on the data coming out of asco 2017 regarding flt3 mutant aml patients
Published 7 years ago β’ 126 plays β’ Length 1:20Download video MP4
Download video MP3
Similar videos
-
0:44
aref al-kali, md, explains sustained inhibition of flt3 when treating aml patients
-
1:32
aref al-kali, md, offers perspective on treating elderly aml patients
-
0:42
aref al-kali, md, discusses the importance of specificity when selecting a flt3 inhibitor
-
1:10
aref al-kali, md, on how hematologists will adopt midostaurin for flt3 aml patients
-
1:06
aref al-kali, md, reflects on the beat aml master trial and individualized therapy for aml patients
-
2:45
acute myeloid leukemia aml animation
-
9:45
discussing flt3-mutated aml: top ash data, triplets, and exciting future strategies
-
4:47
the use of flt3 inhibitors in aml
-
0:32
aref al-kali, md, regarding the leukostat test in conjunction with midostaurin
-
0:25
aref al-kali, md, explains how the cpx 351 data may impact how aml patients are treated if approved
-
1:44
aref al-kali, md, on immunotherapy and its potential role in treating hematological malignancies
-
2:11
flt3-mutated aml data at ash 2021
-
1:39
quantum-first: flt3-itd-specific mrd clearance is associated with improved os in newly diagnosed aml
-
3:28
what is the impact of mrd on the management of patients with πΉπΏπ3-mutated aml
-
7:35
data supporting quizartinib in flt3 r/r aml
-
1:52
the management of r/r flt3-mutated aml
-
0:58
flt3 mutation clearance rate in patients with newly diagnosed aml
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
4:09
quantum-r: quizartinib looks promising for flt3-itd mutated aml
-
1:35
flt3 inhibitor maintenance after allo-sct for aml
-
2:30
flt3 inhibitors - their role in aml
-
5:20
asp2215 successfully inhibits flt3 in high-risk aml patients